LXJ-02

LXJ-02 is a potent inhibitor of EDPs/EBP peptide–protein interaction, with the KD of 117 μM for EDPs. LXJ-02 activates the macrophage-MMP-12 axis to increase MMP-12 expression and degrade ECM components like elastin[1].

Product Specifications

CAS Number

[2672508-37-9]

UNSPSC

12352209

Target

MMP

Type

Peptides

Related Pathways

Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/lxj-02.html

Solubility

10 mM in DMSO

Smiles

C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(=O)N1[C@H](C(N[C@H](C(N)=O)C)=O)CCC1)CO)=O)C)=O)CCC(O)=O)=O)CCC(O)=O)=O)CCC(N)=O)=O)C)=O)CO)(=O)[C@H]2N(C([C@@H](NC(CNC([C@@](NC([C@@H](NC(CCOCCOCCNC(CCOCCOCCNC(CC[C@H](NC(CCCCCCCCCCCCCCCCCCC(O)=O)=O)C(O)=O)=O)=O)=O)[C@H](C)C)=O)(CC)C)=O)=O)CO)=O)CCC2

Molecular Formula

C94H159N19O34

Molecular Weight

2099.37

References & Citations

[1]Yixiang Wang, et al. Design and Synthesis of Novel Ultralong-Acting Peptides as EDP-EBP Interaction Inhibitors for Pulmonary Fibrosis Treatment. J Med Chem. 2024 Apr 25;67 (8) :6624-6637.